First Antiviral Drug Piperazine For Chikungunya

First Antiviral Drug Piperazine For Chikungunya

Health In Focus
RSS Email Print This Page Comment bookmark
Font : A-A+

Highlights:

  • Anti-viral properties of the drug piperazine can be used to treat chikungunya.
  • Piperazine is already in the market for use as deworming treatments against roundworm and pinworm.
  • Instead of developing a new anti-viral agent, Piperazine can be used to reduce the symptoms of chikungunya and treat the infection.
Chikungunya, the viral disease transmitted by mosquitoes can now be treated with the drug piperazine. Research team at the Indian Institute of Technology (IIT) in Roorkee have discovered the anti-viral properties of the drug.
First Antiviral Drug Piperazine For Chikungunya

Dr Shailly Tomar, Biotechnology department, IIT said, "Chikungunya is gradually becoming a major public health concern, with many affected by it every year. There is no vaccine or antiviral drug available in the market for the cure of chikungunya currently."

Piperazine is already available in the market and is commonly used in deworming treatments against roundworm and pinworm. The drug was tested for its virus-fighting property and is confirmed to treat chikungunya. The effect of the drug for chikungunya is attributed to the binding property of capsid protein, present in the Chikungunya virus.


"Our research has showed that piperazine, a drug existing in the market, is successful in curbing the spread and replication of the Chikungunya virus in a lab setting. We are currently testing the molecule on animals hope to take this to clinical trials soon," said Tomar.

Using X-ray crystallographic technique, computational biology and fluorescence techniques the drug was found to be effective to fight viral infection.

Piperazine binds itself with a protein in the virus. There is a hydrophobic pocket on the protein called ;alphavirus capsid protein' to which the virus binds. This pocket is crucial for the replication of the virus and its spread inside a host. This inhibition of the pocket prevents the spread of the virus and can help in treating the virus effectively using existing drugs.

What is Chikungunya?

Chikungunya virus, also known as Buggy Creek Virus, is transmitted by Aedes aegypti mosquito bites. The Aedes aegypti mosquito, a household container breeder and aggressive daytime biter which is attracted to humans, is the primary vector of chikungunya infection to humans.

The virus transmits from mosquitoes to monkeys. Though other species can also be affected, monkeys are the main virus reservoirs. There is no evidence till date, to indicate that there is a person-to-person transmission of the virus causing chikungunya.

Symptoms of Chikungunya

Usually after the bite of the incubated mosquito, it takes 1-12 days for incubation. The symptoms of chikungunya include are categorized based on the severity of the disease. 
  • High fever
  • Pain in the joints, otherwise called arthralgia. The pain is usually severe in the morning and may subsidize during the day.
  • Swelling of joints
  • Vomiting, nausea
  • Rash: fever rash appears in 50% of the cases within 5 days of the onset of the disease.

Chikungunya in Children

 The symptoms vary in children ranging from asymptomatic to severe disease. Children can have minor hemorrhagic manifestations, edema in the lymph, swelling of eyelids and pharyngitis. Watery stools, seizures, lethargy, irritability and excessive crying in addition to fever.

Chikungunya virus can be transmitted from the mother to the child and usually the transmission risk is greater during birth.

The signs of infection appeared around the fourth day and 90% of the infants recover.

Since the disease has severe outcomes, it is vital to treat the infection before the symptoms become severe. There are no specific drugs to cure chikungunya and the treatment given is aimed to relieve the symptoms. There are no effective vaccines developed to prevent chikungunya.

Bottom line

The treatment tested with Piperazine focused on relieving the symptoms associated with the infection. Since developing a new antiviral drug molecule can take over a decade the team used an existing, approved drug and tested to see if it might inhibit or kill pathogenic viruses.

Reference:

  1. Dayaraj Cecilia, Current status of dengue and chikungunya in India, - (http://www.searo.who.int/publications/journals/seajph/seajphv3n1p22.pdf)
  2. Aggarwal M, Kaur R, Saha A, Mudgal R, Yadav R, Dash PK, Parida M, Kumar P, Tomar S. Evaluation of antiviral activity of piperazine against Chikungunya virus targeting hydrophobic pocket of alphavirus capsid protein, Antiviral Res. 2017, doi: 10.1016/j.antiviral.2017.08.015.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Dengue and Homeopathy Chikungunya and Homeopathy Chikungunya Signature Drug Toxicity Drugs Banned in India Postherpetic Neuralgia 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...